Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Relationship of prospective memory to neuropsychological function and antiretroviral adherence.

Contardo C, Black AC, Beauvais J, Dieckhaus K, Rosen MI.

Arch Clin Neuropsychol. 2009 Sep;24(6):547-54. doi: 10.1093/arclin/acp046. Epub 2009 Jul 31.

PMID:
19648150
2.

The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review.

Lovejoy TI, Suhr JA.

J Behav Med. 2009 Oct;32(5):389-405. doi: 10.1007/s10865-009-9212-9. Epub 2009 Mar 17. Review.

PMID:
19291386
3.

HIV-associated prospective memory impairment increases risk of dependence in everyday functioning.

Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I; HIV Neurobehavioral Research Center Group.

Neuropsychology. 2008 Jan;22(1):110-7. doi: 10.1037/0894-4105.22.1.110.

PMID:
18211160
4.

Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.

Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, Bombana E, Suter F.

HIV Clin Trials. 2007 Sep-Oct;8(5):282-92.

PMID:
17956829
5.

The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.

Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, Montaner J, Hogg RS.

AIDS. 2007 May 31;21(9):1175-83.

PMID:
17502728
6.

Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status.

Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Marion SD, Levine AJ, Durvasula RS.

Health Psychol. 2007 Jan;26(1):40-9.

PMID:
17209696
7.

Drug use and medication adherence among HIV-1 infected individuals.

Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, Myers HF, Longshore D.

AIDS Behav. 2007 Mar;11(2):185-94.

PMID:
16897351
8.

Variations in patterns of highly active antiretroviral therapy (HAART) adherence.

Levine AJ, Hinkin CH, Castellon SA, Mason KI, Lam MN, Perkins A, Robinet M, Longshore D, Newton T, Myers H, Durvasula RS, Hardy DJ.

AIDS Behav. 2005 Sep;9(3):355-62.

PMID:
16088365
9.

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS.

J Infect Dis. 2005 Feb 1;191(3):339-47. Epub 2004 Dec 22.

PMID:
15633092
10.

Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection.

Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK; HNRC Group.

J Clin Exp Neuropsychol. 2004 May;26(3):307-19.

PMID:
15512922
11.

Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse.

Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, Stefaniak M.

AIDS. 2004 Jan 1;18 Suppl 1:S19-25.

PMID:
15075494
12.

Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients.

Casado JL, Sabido R, Perez-Elías MJ, Antela A, Oliva J, Dronda F, Mejía B, Fortún J.

Antivir Ther. 1999;4(3):157-61.

PMID:
12731755
13.

Virologic correlates of adherence to antiretroviral medications and therapeutic failure.

Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A; AdICoNA Study Group.

J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S118-22. Review.

PMID:
12562033
14.

Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity.

Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M.

Neurology. 2002 Dec 24;59(12):1944-50.

PMID:
12499488
15.

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.

Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, Stone VE, Smith DK, Schoenbaum EE; HER Study Group.

AIDS. 2002 Nov 8;16(16):2175-82.

PMID:
12409739
16.

Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection.

Nieuwkerk PT, Gisolf EH, Reijers MH, Lange JM, Danner SA, Sprangers MA; NATIVE Study Group; PROMETHEUS Study Group; ADAM Study Group.

AIDS. 2001 Oct 19;15(15):1985-91.

PMID:
11600827
17.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
18.

Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA.

Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M; Adolescent Medicine HIV/AIDS Research Network.

AIDS Care. 2001 Feb;13(1):27-40.

PMID:
11177463
19.

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N.

Ann Intern Med. 2000 Jul 4;133(1):21-30. Erratum in: Ann Intern Med 2002 Feb 5;136(3):253.

PMID:
10877736
20.

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A.

AIDS. 2000 Mar 10;14(4):357-66.

PMID:
10770537
Items per page

Supplemental Content

Write to the Help Desk